These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 30296897)

  • 1. Cardiovascular Pharmacogenomics: Does It Matter If You're Black or White?
    De T; Park CS; Perera MA
    Annu Rev Pharmacol Toxicol; 2019 Jan; 59():577-603. PubMed ID: 30296897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy.
    Mango R; Vecchione L; Raso B; Borgiani P; Brunetti E; Mehta JL; Lauro R; Romeo F; Novelli G
    Expert Opin Pharmacother; 2005 Dec; 6(15):2565-76. PubMed ID: 16316297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic Ancestry Inference for Pharmacogenomics.
    Jordan IK; Sharma S; Nagar SD; Valderrama-Aguirre A; Mariño-Ramírez L
    Methods Mol Biol; 2022; 2547():595-609. PubMed ID: 36068478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Advantages and Challenges of Diversity in Pharmacogenomics: Can Minority Populations Bring Us Closer to Implementation?
    Zhang H; De T; Zhong Y; Perera MA
    Clin Pharmacol Ther; 2019 Aug; 106(2):338-349. PubMed ID: 31038731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrate pharmacogenomics: expanding past the genome.
    House JS; Motsinger-Reif AA
    Pharmacogenomics; 2020 Mar; 21(4):293-306. PubMed ID: 32180510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomics and management of cardiovascular disease.
    Howe LA
    Nurse Pract; 2009 Aug; 34(8):28-35; quiz 36. PubMed ID: 19638892
    [No Abstract]   [Full Text] [Related]  

  • 7. Genetic databases in pharmacogenomics: the Frequency of Inherited Disorders Database (FINDbase).
    Georgitsi M; Patrinos GP
    Methods Mol Biol; 2013; 1015():321-36. PubMed ID: 23824866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics, ancestry and clinical decision making for global populations.
    Ramos E; Doumatey A; Elkahloun AG; Shriner D; Huang H; Chen G; Zhou J; McLeod H; Adeyemo A; Rotimi CN
    Pharmacogenomics J; 2014 Jun; 14(3):217-22. PubMed ID: 23835662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standardized Biogeographic Grouping System for Annotating Populations in Pharmacogenetic Research.
    Huddart R; Fohner AE; Whirl-Carrillo M; Wojcik GL; Gignoux CR; Popejoy AB; Bustamante CD; Altman RB; Klein TE
    Clin Pharmacol Ther; 2019 May; 105(5):1256-1262. PubMed ID: 30506572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer pharmacogenomics: implications on ethnic diversity and drug response.
    Patel JN
    Pharmacogenet Genomics; 2015 May; 25(5):223-30. PubMed ID: 25751395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic determinants of response to cardiovascular drugs.
    Wells QS; Delaney JT; Roden DM
    Curr Opin Cardiol; 2012 May; 27(3):253-61. PubMed ID: 22382501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice.
    Chatelin J; Stathopoulou MG; Arguinano AA; Xie T; Visvikis-Siest S
    Curr Pharm Biotechnol; 2017; 18(3):231-241. PubMed ID: 28117005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of single nucleotide polymorphisms in pharmacogenomics and their association with human diseases.
    Chaudhary R; Singh B; Kumar M; Gakhar SK; Saini AK; Parmar VS; Chhillar AK
    Drug Metab Rev; 2015 Aug; 47(3):281-90. PubMed ID: 25996670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of single-nucleotide polymorphism maps in pharmacogenomics.
    McCarthy JJ; Hilfiker R
    Nat Biotechnol; 2000 May; 18(5):505-8. PubMed ID: 10802616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomics and drug response in cardiovascular disorders.
    Siest G; Jeannesson E; Berrahmoune H; Maumus S; Marteau JB; Mohr S; Visvikis S
    Pharmacogenomics; 2004 Oct; 5(7):779-802. PubMed ID: 15469403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics: the way forward.
    Terra SG; Johnson JA
    Am J Cardiovasc Drugs; 2002; 2(5):287-96. PubMed ID: 14727958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenomics to Revive Drug Development in Cardiovascular Disease.
    Dubé MP; de Denus S; Tardif JC
    Cardiovasc Drugs Ther; 2016 Feb; 30(1):59-64. PubMed ID: 26768480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. State of Art of Cancer Pharmacogenomics in Latin American Populations.
    López-Cortés A; Guerrero S; Redal MA; Alvarado AT; Quiñones LA
    Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28545225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug target pharmacogenomics: an overview.
    Johnson JA
    Am J Pharmacogenomics; 2001; 1(4):271-81. PubMed ID: 12083959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the distribution of genetic markers of pharmacogenomics relevance in Brazilian and Mexican populations.
    Bonifaz-Peña V; Contreras AV; Struchiner CJ; Roela RA; Furuya-Mazzotti TK; Chammas R; Rangel-Escareño C; Uribe-Figueroa L; Gómez-Vázquez MJ; McLeod HL; Hidalgo-Miranda A; Parra EJ; Fernández-López JC; Suarez-Kurtz G
    PLoS One; 2014; 9(11):e112640. PubMed ID: 25419701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.